Annovis Bio (ANVS)
Develops oral buntanetap for Alzheimer's and Parkinson's disease.
Something off on this page? Send us feedback.
Advances buntanetap, an investigational oral therapy for Alzheimer's and Parkinson's disease. The founder-led company has no commercialized products and has historically funded operations through common-stock and warrant issuances.
Develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. The central program was licensed from the U.S. National Institute on Aging, and the company has no history of commercializing a pharmaceutical product.
Operations principally focus on preclinical and clinical studies. The pivotal early-Alzheimer's study is fully enrolled at U.S. sites. Founder, President and CEO Maria L. Maccecchini leads the clinical-stage organization. Commercialization of buntanetap depends on completing pivotal trials, receiving marketing approval, manufacturing at commercial scale, building sales and marketing capabilities, and securing additional capital.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 7, 2026 | Roth Capital | Initiate | Rating: — | |
| Feb 10, 2025 | D. Boral Capital | Downgrade | ||
| Oct 25, 2024 | Maxim Group | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.7M · Total debt $0 · Total assets $22.0M · Shareholders' equity −$4.3M
- Revenue
- $0
- Operating income
- −$14.4M
- Net income
- −$14.8M
No dividends on record.
| Institutions | 25.47% | 10.85M shares | |
|---|---|---|---|
| 69 holders · as of Jun 30, 2026 | |||
| Insiders | 10.80% | 4.60M shares | |
| 5 holders · as of May 21, 2026 | |||
| Strategic holders | 6.51% | 2.78M shares | |
| 1 holder · as of Aug 14, 2026 | |||
| Other | 57.22% | 24.38M shares | |
| remainder | |||
42.61M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Michael B. HoffmanInsiderdirector | 7.90% | 3.36M | filed May 21, 2026 |
Highbridge Capital Management, LLCStrategic | 6.51% | 2.78M | filed Aug 14, 2026 |
Empery Asset Management, LPInstitution | 5.64% | 2.40M | as of Jun 30, 2026 |
Marshall Wace, LLPInstitution | 4.32% | 1.84M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.87% | 1.65M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Michael B. Hoffman | director | +76,344 | $1.87 |
| Apr 2, 2026 | Michael B. Hoffman | director | +713,800 | $2.10 |
| Dec 8, 2025 | Michael B. Hoffman | director | +45,000 | $4.31 |
| Nov 24, 2025 | Michael B. Hoffman | director | +39,200 | $4.08 |
| Nov 21, 2025 | Michael B. Hoffman | director | +20,000 | $3.50 |
- Eli Lilly
Approved early-AD amyloid therapy with monthly IV dosing
- Biogen
Co-commercialized early-AD anti-amyloid treatment
- AbbVie
Late-stage once-daily therapy program for early Parkinson's disease
- Bristol-Myers Squibb
Phase 2 anti-MTBR-tau antibody program for early Alzheimer's disease
- Cognition Therapeutics
Once-daily oral candidate in an ongoing early-AD Phase 2 trial
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Annovis Bio | $1.30 | +2.78% | $53.6M | — | — | — | — |
| Eli Lilly | $1,162.30 | −0.67% | $1.10T | 39.3 | 28.4 | 13.8 | +47.7% |
| Biogen | $226.55 | +0.53% | $33.30B | 39.9 | 17.1 | 3.3 | +3.4% |
| AbbVie | $267.10 | +0.71% | $468.77B | 74.8 | 17.6 | 7.3 | +10.2% |
| Bristol-Myers Squibb | $61.82 | −0.69% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Cognition Therapeutics | $0.9717 | −0.98% | $87.8M | — | — | — | — |
| Median | 39.6 | 17.3 | 5.3 | +8.0% |